Intellikine is
a venture-backed company focused on the development of potent,
selective small molecule inhibitors of the PI3K/Akt/mTOR pathway
for the treatment of cancer, inflammation and autoimmune disorders.
Our founders, management team, and advisors include experts in
research and early development of drugs against this important
family of targets. In addition, we work with leading clinical
experts in the diseases we intend to evaluate.
Our most advanced compound, INK128, a selective TORC1/2 inhibitor
for the treatment of solid tumor malignancies is in early clinical
studies. In addition to INK128, we are advancing a strong pipeline
of isoform-selective PI3K inhibitors as potential therapies for
a variety of life-threatening diseases.
At Intellikine, we are committed to build the industry’s leading pipeline of small molecule drugs against the PI3K/Akt/mTOR pathway and to advance this pipeline as quickly as possible to create drugs that will improve the lives of patients.